Brussels, 15 September 2006
- UCB announced today the creation of the Chair in Management of Inflammatory Bowel Disease to support the research of Professor Severine Vermeire and Professor Paul Rutgeerts of the division of Gastroenterology of the university hospital at the Katholieke Universiteit Leuven (KUL). The research concerns the mechanisms of action of biological therapies in IBD and predictive factors for outcome.
UCB's sponsorship of this respected academic chair at an institution recognised for its leadership in the study and treatment of gastroenterology is part of UCB's ongoing commitment to supporting research into inflammatory disease and embodies the Company's core values of remaining dedicated to patients and making a real difference to the lives of people all over the world. UCB submitted the license applications for its first biologic, CIMZIA(TM) (certolizumab pegol) for the treatment of Crohn's disease (an inflammatory bowel disease) with the regulatory authorities in both the USA and Europe earlier this year.
About UCB
UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on the Euronext Brussels Exchange.
Inquiries, please contact:
Jean-Christophe Donck
Vice President
Corporate Communications and Investor Relations
Phone +32.2.559.9346
Email jc.donck@ucb-group.com
For the pdf-version of this press release, please click on the link below:
